Uso de anticorpo monoclonal no tratamento de Mieloma Múltiplo
DOI:
https://doi.org/10.34119/bjhrv6n3-293Keywords:
imunoterapia, Tumor de Células Linfoides, doenças onco-hematológicas, prognósticoAbstract
A pesquisa justifica-se pela atual situação epidemiológica do mieloma múltiplo (MM), que apresenta incidência crescente com o avançar da idade contribuindo para o aumento da fragilidade da população idosa. O objetivo da revisão foi abordar as principais evidências científicas a respeito do uso de anticorpos monoclonais para o tratamento do mieloma múltiplo recidivante/refratário. Por meio de uma revisão integrativa de literatura realizada nas bases de dados eletrônicos: Literatura Latino-Americana em Ciências da Saúde (LILACS), Medical Literature and Retrieval System Online (Medline), PubMed e Scielo. Dos 54 artigos inicialmente avaliados, somente 27 atendiam os critérios estabelecidos, assim foi possível concluir que os tratamentos à base de Isatuximabe associada dexametasona/ carfizomibe/ lenalidomida ou dexametasona/ pomalidomida, obteve melhores taxas de sobrevida global (PFS em 2 anos 75,5%). Daratumumabe associado a pomalidomida/ dexametasona ou carfizomibe/ dexametasona ou lenalidomida/ dexametasona ou bortezomibe/ dexametasona também obtiveram aumento das taxas de resposta global (ORR 84%). A partir desse artigo foi possível concluir a eficácia clínica significativa, haja vista a profundidade de resposta obtida com os regimes de tratamento anteriormente citados.
References
ARMAND, Philippe; LESOKHIN, Alexander; BORRELLO, Ivan; TIMMERMAN, John; GUTIERREZ, Martin; ZHU, Lili; MCKIVER, Mihaela Popa; ANSELL, Stephen M.. A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies. Leukemia, [S.L.], v. 35, n. 3, p. 777-786, 29 jun. 2020. Springer Science and Business Media LLC. http://dx.doi.org/10.1038/s41375-020-0939-1
Bahlis NJ, Dimopoulos MA, White DJ, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020;34(7):1875-1884. doi:10.1038/s41375-020-0711-6
Banaszkiewicz M, Małyszko J, Vesole DH, et al. New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia. J Clin Med. 2019;8(11):1828. Published 2019 Nov 1. doi:10.3390/jcm8111828
BEKSAC, Meral; AYDIN, Yildiz; GOKER, Hakan; TURGUT, Mehmet; BESISIK, Sevgi Kalayoglu; CAGIRGAN, Seckin; TUGLULAR, Tulin; VURAL, Filiz; YAGCI, Munci; ALACACIOGLU, Inci. Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma. Clinical Lymphoma Myeloma And Leukemia, [S.L.], v. 20, n. 8, p. 474-484, ago. 2020. Elsevier BV. http://dx.doi.org/10.1016/j.clml.2020.02.017.
Bub, Carolina Bonet et al. Transfusion management for patients taking an anti-CD38 monoclonal antibody. Hematology, Transfusion and Cell Therapy [online]. 2018, v. 40, n. 1 [Accessed 19 November 2021] , pp. 25-29. Available from: https://doi.org/10.1016/j.bjhh.2017.09.003.
CONTEJEAN, Adrien; LAROUSSERIE, Frédérique; BOUSCARY, Didier; DOHAN, Anthony; DEAU-FISCHER, Bénédicte; SZWEBEL, Tali-Anne; DHOOGE, Marion; TERRIS, Benoit; VIGNON, Marguerite. A colonic mass revealing a disseminated crystal storing histiocytosis secondary to indolent multiple myeloma: a case report with literature review. Bmc Gastroenterology, [S.L.], v. 20, n. 1, p. 1-5, 31 jul. 2020. Springer Science and Business Media LLC. http://dx.doi.org/10.1186/s12876-020-01364-2
CHARI, Ajai; MARTINEZ-LOPEZ, Joaquín; MATEOS, María-Victoria; BLADÉ, Joan; BENBOUBKER, Lotfi; ORIOL, Albert; ARNULF, Bertrand; RODRIGUEZ-OTERO, Paula; PINEIRO, Luis; JAKUBOWIAK, Andrzej. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood, [S.L.], v. 134, n. 5, p. 421-431, 1 ago. 2019. American Society of Hematology. http://dx.doi.org/10.1182/blood.2019000722.
Crusoe EQ, Higashi F, Martinez G, et al. Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation. Hematol Transfus Cell Ther. 2020;42(2):118-124. doi:10.1016/j.htct.2019.05.004
CURTI, Brendan D; KOGUCHI, Yoshinobu; LEIDNER, Rom s; ROLIG, Annah s; STURGILL, Elizabeth R; SUN, Zhaoyu; WU, Yaping; RAJAMANICKAM, Venkatesh; BERNARD, Brady; HILGART-MARTISZUS, Ian. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor. Journal For Immunotherapy Of Cancer, [S.L.], v. 9, n. 4, p. 1-12, abr. 2021. BMJ. http://dx.doi.org/10.1136/jitc-2021-002371.
Dimopoulos MA, Leleu X, Moreau P, et al. Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. Leukemia. 2021;35(2):562-572. doi:10.1038/s41375-020-0868-z.
Dimopoulos MA, Lonial S, White D, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020;10(9):91. Published 2020 Sep 4. doi:10.1038/s41408-020-00357-4.
FERNANDEZ-LAZARO, Diego et al . Agentes inmunomoduladores (IMiDs): herramientas para el tratamiento del mieloma múltiple. Rev. méd. Chile, Santiago , v. 146, n. 12, p. 1444-1451, dic. 2018 . Disponible en <http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018001201444&lng=es&nrm=iso>. accedido en 19 nov. 2021. http://dx.doi.org/10.4067/s0034-98872018001201444.
GAY, Francesca; JACKSON, Graham; ROSIÑOL, Laura; HOLSTEIN, Sarah A.; MOREAU, Philippe; SPADA, Stefano; DAVIES, Faith; LAHUERTA, Juan José; LELEU, Xavier; BRINGHEN, Sara. Maintenance Treatment and Survival in Patients With Myeloma. Jama Oncology, [S.L.], v. 4, n. 10, p. 1389, 1 out. 2018. American Medical Association (AMA). http://dx.doi.org/10.1001/jamaoncol.2018.2961.
HILLENGASS, Jens; USMANI, Saad; RAJKUMAR, S Vincent; DURIE, Brian G M; MATEOS, María-Victoria; LONIAL, Sagar; JOAO, Cristina; ANDERSON, Kenneth C; GARCÍA-SANZ, Ramón; RIVA, Eloísa. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. The Lancet Oncology, [S.L.], v. 20, n. 6, p. 302-312, jun. 2019. Elsevier BV. http://dx.doi.org/10.1016/s1470-2045(19)30309-2.
HUANG, Shang-Yi; YOON, Sung-Soo; SHIMIZU, Kazuyuki; CHNG, Wee Joo; CHANG, Cheng-Shyong; WONG, Raymond Siu-Ming; GAO, Seasea; WANG, Yang; GORDON, Steve W.; GLENNANE, Anthony. Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: an international, double-blind, randomized controlled phase 3 study⠴asian subgroup analysis. Advances In Therapy, [S.L.], v. 37, n. 7, p. 3404-3416, 10 jun. 2020. Springer Science and Business Media LLC. http://dx.doi.org/10.1007/s12325-020-01395-x.
Hulin C, Beksac M, Goodman HJ, et al. Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma. Blood Cancer J. 2021;11(10):169. Published 2021 Oct 20. doi:10.1038/s41408-021-00562-9
HUNGRIA, Vania; MARTÍNEZ-BAÑOS, Deborah M.; MATEOS, María-Victoria; DIMOPOULOS, Meletios A.; CAVO, Michele; HEEG, Bart; GARCIA, Andrea; LAM, Annette; MACHNICKI, Gerardo; HE, Jianming. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: propensity score matching analysis. Advances In Therapy, [S.L.], v. 37, n. 12, p. 4996-5009, 16 out. 2020. Springer Science and Business Media LLC. http://dx.doi.org/10.1007/s12325-020-01521-9.
IDE, Takafumi; OSAWA, Mayu; SANGHAVI, Kinjal; VEZINA, Heather E.. Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma. Cancer Chemotherapy And Pharmacology, [S.L.], v. 89, n. 1, p. 129-140, 26 nov. 2021. Springer Science and Business Media LLC. http://dx.doi.org/10.1007/s00280-021-04365-4.
INCA. Atlas On-line de Mortalidade. Disponível em: https://mortalidade.inca.gov.br/MortalidadeWeb/pages/Modelo03/consultar.xhtml#panelResultado. Acesso em: 30 maio 2022.
Kazandjian D, Dew A, Hill E, et al. Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma. Oncologist. 2021;26(4):288-e541. doi:10.1002/onco.13712
KOIWAI, Kimiko; EL‐CHEIKH, Raouf; THAI, Hoai‐Thu; BRILLAC, Claire; FAU, Jean‐Baptiste; VEYRAT‐FOLLET, Christine; RISSE, Marie‐Laure; VELDE, Helgi; SEMIOND, Dorothée; NGUYEN, Laurent. PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma. Cpt: Pharmacometrics & Systems Pharmacology, [S.L.], v. 10, n. 8, p. 928-940, 8 jul. 2021. Wiley. http://dx.doi.org/10.1002/psp4.12666.
Kumar, S., Rajkumar, V., Kyle, R. et al. Multiple myeloma. Nat Rev Dis Primers 3, 17046 (2017). https://doi.org/10.1038/nrdp.2017.46
LAHUERTA, Juan-Jose; PAIVA, Bruno; VIDRIALES, Maria-Belen; CORDÓN, Lourdes; CEDENA, Maria-Teresa; PUIG, Noemi; MARTINEZ-LOPEZ, Joaquin; ROSIÑOL, Laura; GUTIERREZ, Norma C.; MARTÍN-RAMOS, María-Luisa. Depth of Response in Multiple Myeloma: a pooled analysis of three pethema/gem clinical trials. Journal Of Clinical Oncology, [S.L.], v. 35, n. 25, p. 2900-2910, 1 set. 2017. American Society of Clinical Oncology (ASCO). http://dx.doi.org/10.1200/jco.2016.69.2517.
LANDGREN, C. Ola; CHARI, Ajai; COHEN, Yael C.; SPENCER, Andrew; VOORHEES, Peter; ESTELL, Jane A.; SANDHU, Irwindeep; JENNER, Matthew W.; WILLIAMS, Catherine; CAVO, Michele. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (centaurus). Leukemia, [S.L.], v. 34, n. 7, p. 1840-1852, 5 fev. 2020. Springer Science and Business Media LLC. http://dx.doi.org/10.1038/s41375-020-0718-z
LAPEÑA-CELAYA, José Antonio de; AGUILAR-LUEVANO, Jocelyn; ALCIVAR-CEDEÑO, Luisa Ma.; ÁLVAREZ-VERA, José L.; ANAYA-CUELLAR, Irene; AÑORVE-HERNÁNDEZ, Erika; ARANA-LUNA, Luara L.; ARTEAGA-ORTÍZ, Luis; BÁEZ-ISLAS, Pamela E.; BANDA-GARCÍA, Luisa I.. Consenso Mexicano de Mieloma Múltiple. Gaceta de México, [S.L.], v. 156, n. 92, p. 1-12, 27 out. 2020. Publicidad Permanyer, SLU. http://dx.doi.org/10.24875/gmm.m20000393.
LEGÜES, María Eugenia; MORALES, Paulina; VALENZUELA, Mercedes; ENCINA, Andrea; MARTÍ, María José; BASCUÑÁN, Claudia; CORNEJO, Paulina; PEÑA, Camila; UNDURRAGA, María Soledad. Características citogenéticas y detección de anormalidades de alto riesgo en mieloma múltiple. Revista Médica de Chile, [S.L.], v. 147, n. 1, p. 61-64, 2019. SciELO Agencia Nacional de Investigacion y Desarrollo (ANID). http://dx.doi.org/10.4067/s0034-98872019000100061.
LEYPOLDT, Lisa B.; BESEMER, Britta; ASEMISSEN, Anne Marie; HÄNEL, Mathias; BLAU, Igor Wolfgang; GÖRNER, Martin; KO, Yon-Dschun; REINHARDT, Hans Christian; STAIB, Peter; MANN, Christoph. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the gmmg-concept trial. Leukemia, [S.L.], v. 36, n. 3, p. 885-888, 3 nov. 2021. Springer Science and Business Media LLC. http://dx.doi.org/10.1038/s41375-021-01431-x.
Mateos MV, Sonneveld P, Hungria V, et al. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clin Lymphoma Myeloma Leuk. 2020;20(8):509-518. doi:10.1016/j.clml.2019.09.623
Mateos MV, Spencer A, Nooka AK, et al. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. Haematologica. 2020;105(2):468-477. Published 2020 Jan 31. doi:10.3324/haematol.2019.217448
MICHELS, Thomas C. et al. Multiple Myeloma: Diagnosis and Treatment. American Academy Of Family Physicians, Washington, p. 1-12, 15 mar. 2017. https://www.aafp.org/afp/2017/0315/p373.html
Mikhael J, Belhadj-Merzoug K, Hulin C, et al. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J. 2021;11(5):89. Published 2021 May 12. doi:10.1038/s41408-021-00478-4
MIKHAEL, Joseph; RICHTER, Joshua; VIJ, Ravi; COLE, Craig; ZONDER, Jeffrey; KAUFMAN, Jonathan L.; BENSINGER, William; DIMOPOULOS, Meletios; LENDVAI, Nikoletta; HARI, Parameswaran. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. Leukemia, [S.L.], v. 34, n. 12, p. 3298-3309, 14 maio 2020. Springer Science and Business Media LLC. http://dx.doi.org/10.1038/s41375-020-0857-2.
Moreau P, Dimopoulos MA, Yong K, et al. Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design. Future Oncol. 2020;16(2):4347-4358. doi:10.2217/fon-2019-0431.
MOREAU, Philippe; GHORI, Razi; FAROOQUI, Mohammed; MARINELLO, Patricia; MIGUEL, Jesus San. Pembrolizumab combined with carfilzomib and low‐dose dexamethasone for relapsed or refractory multiple myeloma: cohort 2 of the phase i keynote⠰023 study. British Journal Of Haematology, [S.L.], v. 194, n. 1, p. 48-51, 10 jun. 2021. Wiley. http://dx.doi.org/10.1111/bjh.17448.
RAJKUMAR, S. Vincent. Multiple myeloma: every year a new standard?. Hematological Oncology, [S.L.], v. 37, n. 1, p. 62-65, jun. 2019. Wiley. http://dx.doi.org/10.1002/hon.2586.
Richardson PG, Oriol A, Larocca A, et al. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. J Clin Oncol. 2021;39(7):757-767. doi:10.1200/JCO.20.02259
RICHARDSON, Paul G.; LEE, Hans C.; ABDALLAH, Al-Ola; COHEN, Adam D.; KAPOOR, Prashant; VOORHEES, Peter M.; HOOS, Axel; WANG, Karrie; BARON, January; PIONTEK, Trisha. Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal dreamm-2 study. Blood Cancer Journal, [S.L.], v. 10, n. 10, p. 1-11, 23 out. 2020. Springer Science and Business Media LLC. http://dx.doi.org/10.1038/s41408-020-00369-0.
RICHARDSON, Paul G; HARRISON, Simon J; BRINGHEN, Sara; SCHJESVOLD, Fredrik; YONG, Kwee; CAMPANA, Frank; LE-GUENNEC, Solenn; MACÉ, Sandrine; A DIMOPOULOS, Meletios. Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the phase iii icaria-mm study. Future Oncology, [S.L.], v. 17, n. 34, p. 4797-4812, dez. 2021. Future Medicine Ltd. http://dx.doi.org/10.2217/fon-2021-0568.
SCHOENBECK, Kelly L; WILDES, Tanya M. Updated Perspectives on the Management of Multiple Myeloma in Older Patients: focus on lenalidomide. Clinical Interventions In Aging, [S.L.], v. 15, p. 619-633, maio 2020. Informa UK Limited. http://dx.doi.org/10.2147/cia.s196087.
Siegel DS, Schiller GJ, Samaras C, et al. Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment. Leukemia. 2020;34(12):3286-3297. doi:10.1038/s41375-020-0813-1
SOEKOJO, Cinnie Yentia; OOI, Melissa; MEL, Sanjay de; CHNG, Wee Joo. Immunotherapy in Multiple Myeloma. Cells, [S.L.], v. 9, n. 3, p. 601, 3 mar. 2020. MDPI AG. http://dx.doi.org/10.3390/cells9030601.
SUBRAMANIYAN, Rajeswari; SATHESHKUMAR, Ramaprabahari; PEREIRA, Karishma Rosann. Role of daratumumab in transfusion medicine: a must know entity. Revista Brasileira de Hematologia e Hemoterapia, [S.L.], v. 39, n. 4, p. 375-378, out. 2017. Elsevier BV. http://dx.doi.org/10.1016/j.bjhh.2017.07.002.
Usmani SZ, Hoering A, Ailawadhi S, et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol. 2021;8(1):e45-e54. doi:10.1016/S2352-3026(20)30354-9
USMANI, Saad Z.; KARANES, Chatchada; BENSINGER, William I.; D’SOUZA, Anita; RAJE, Noopur; TUCHMAN, Sascha A.; SBOROV, Douglas; LAUBACH, Jacob P.; BIANCHI, Giada; KANAGAVEL, Dheepak. Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. Leukemia, [S.L.], v. 35, n. 12, p. 3526-3533, 28 maio 2021. Springer Science and Business Media LLC. http://dx.doi.org/10.1038/s41375-021-01262-w.
VIDAL, Thaís Jeronimo; FIGUEIREDO, Tatiana Aragão; PEPE, Vera Lúcia Edais. O mercado brasileiro de anticorpos monoclonais utilizados para o tratamento de câncer. Cadernos de Saúde Pública, [S.L.], v. 34, n. 12, p. 1-14, 29 nov. 2018. FapUNIFESP (SciELO). http://dx.doi.org/10.1590/0102-311x00010918.
Xu XS, Moreau P, Usmani SZ, et al. Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. Adv Ther. 2020;37(4):1464-1478. doi:10.1007/s12325-020-01247-8
